Collegium Pharmaceutical, Inc. (FRA:354)

Market Cap	1.21B +27.0%
Revenue (ttm)	645.25M +26.3%
Net Income	49.81M -34.0%
EPS	1.39 -24.8%
Shares Out	n/a
PE Ratio	24.24
Forward PE	4.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	38.20
Previous Close	38.20
Day's Range	38.20 - 38.20
52-Week Range	22.00 - 42.00
Beta	n/a
RSI	45.44
Earnings Date	Feb 26, 2026

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 357
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 354

Financial Performance

In 2024, Collegium Pharmaceutical's revenue was $631.45 million, an increase of 11.41% compared to the previous year's $566.77 million. Earnings were $69.19 million, an increase of 43.68%.

Financial numbers in USD